Home › Companies › Castle Biosciences, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Castle Biosciences, Inc.’s Form 8-K, filed 2026-05-29 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Explore Castle Biosciences, Inc. in the interactive database Compare manager voting policies
These tallies are Castle Biosciences, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-05-29 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Ellen Goldberg | 15,455,265 | -- | -- | 7,118,166 | 2,415,788 | Majority: yes |
| Elect Director: Miles D. Harrison | 15,607,369 | -- | -- | 6,966,062 | 2,415,788 | Majority: yes |
| Elect Director: Tiffany P. Olson | 14,380,655 | -- | -- | 8,192,776 | 2,415,788 | Majority: yes |
| Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection of KPMG LLP by the Audit Committee of the Company's Board of Directors as the Company's independent | 24,531,366 | 445,666 | 12,187 | -- | -- | Majority: yes |
| Proposal 3. Approval of the Compensation of the Company's Named Executive Officers The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's definitiv | 21,280,180 | 1,281,394 | 11,857 | -- | 2,415,788 | Majority: yes |
| Proposal 4. Approval of the Company's Non-Employee Director Compensation Policy The Company's stockholders approved the Company's non-employee director compensation policy as described in the Proxy Statement. | 21,394,330 | 1,130,133 | 48,968 | -- | 2,415,788 | Majority: yes |
Source: Castle Biosciences, Inc., Form 8-K, filed with the SEC on 2026-05-29 — read the filing on EDGAR.
Each item below shows how the 228 asset managers that disclosed a Castle Biosciences, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 8 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Castle Biosciences, Inc.’s own tally for this item (“Proposal 3. Approval of the Compensation of the Company's Named Executive Officers The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the”): 21,280,180 for, 1,281,394 against, per its Form 8-K filed 2026-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 30,295,965 outstanding shares: 70% for, 4% against (74% of the company cast a for/against vote).
The 226 asset managers below cast 95% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 2,837,898 | 0 | 0 | 0 | For |
| RTW INVESTMENTS, LP | 2,758,335 | 0 | 0 | 0 | For |
| Vanguard | 2,248,935 | 3 | 0 | 0 | For |
| Fidelity | 1,399,350 | 0 | 0 | 0 | For |
| Portolan Capital Management, LLC | 1,350,283 | 0 | 0 | 0 | For |
| PRINCIPAL GLOBAL INVESTORS | 1,117,727 | 0 | 0 | 0 | For |
| Principal | 754,854 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 728,100 | 0 | 0 | 0 | For |
| State Street | 683,314 | 0 | 0 | 0 | For |
| Allianz | 431 | 666,541 | 0 | 0 | Against |
| Nuveen | 599,024 | 0 | 0 | 0 | For |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 525,260 | 0 | 0 | 0 | For |
| Charles Schwab | 483,745 | 0 | 0 | 0 | For |
| WASATCH ADVISORS LP | 454,225 | 0 | 0 | 0 | For |
| WASATCH FUNDS TRUST | 448,328 | 0 | 0 | 0 | For |
| Dimensional | 429,498 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 386,425 | 0 | 0 | 0 | For |
| TIAA | 358,474 | 0 | 0 | 0 | For |
| ACADIAN ASSET MANAGEMENT LLC | 310,738 | 19,012 | 0 | 0 | For |
| Allspring | 307,784 | 0 | 0 | 0 | For |
| Renaissance | 270,542 | 0 | 0 | 0 | For |
| BUFFALO FUNDS | 264,287 | 0 | 0 | 0 | For |
| PALISADE CAPITAL MANAGEMENT, LP | 252,434 | 0 | 0 | 0 | For |
| Northern Trust | 250,467 | 0 | 0 | 0 | For |
| NEW YORK STATE COMMON RETIREMENT FUND | 0 | 233,046 | 0 | 0 | Against |
Showing the 25 largest of 226 asset managers. See all 226 in the interactive database.
Combines 4 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Castle Biosciences, Inc.’s own tally for this item (“Proposal 4. Approval of the Company's Non-Employee Director Compensation Policy The Company's stockholders approved the Company's non-employee director compensation policy as described in the Proxy Statement.”): 21,394,330 for, 1,130,133 against, per its Form 8-K filed 2026-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 30,295,965 outstanding shares: 71% for, 4% against (74% of the company cast a for/against vote).
The 74 asset managers below cast 99% of the shares they voted on this item FOR (9,161,873 for, 109,387 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,023,906 | 3 | 0 | 0 | For |
| BlackRock | 1,561,151 | 0 | 0 | 0 | For |
| Fidelity | 1,349,200 | 0 | 0 | 0 | For |
| Principal | 754,854 | 0 | 0 | 0 | For |
| WASATCH FUNDS TRUST | 448,328 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 386,425 | 0 | 0 | 0 | For |
| TIAA | 358,474 | 0 | 0 | 0 | For |
| Dimensional | 336,242 | 0 | 0 | 0 | For |
| BUFFALO FUNDS | 264,287 | 0 | 0 | 0 | For |
| Charles Schwab | 241,865 | 0 | 0 | 0 | For |
| Allspring | 147,121 | 0 | 0 | 0 | For |
| EA Series Trust | 132,184 | 0 | 0 | 0 | For |
| State Street | 128,647 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 123,000 | 0 | 0 | 0 | For |
| Nuveen | 107,524 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 103,702 | 0 | 0 | Against |
| American Century | 78,975 | 0 | 0 | 0 | For |
| PRINCIPAL VARIABLE CONTRACTS FUNDS INC | 63,600 | 0 | 0 | 0 | For |
| Equitable | 63,424 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 46,712 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 46,342 | 0 | 0 | 0 | For |
| FORMULA GROWTH LTD | 46,000 | 0 | 0 | 0 | For |
| Lincoln Financial | 43,394 | 0 | 0 | 0 | For |
| Putnam | 37,658 | 0 | 0 | 0 | For |
| JPMorgan | 36,830 | 0 | 0 | 0 | For |
Showing the 25 largest of 74 asset managers. See all 74 in the interactive database.
Combines 2 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Castle Biosciences, Inc.’s own tally for this item (“Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection of KPMG LLP by the Audit Committee of the Company's Board of Directors as the C”): 24,531,366 for, 445,666 against, per its Form 8-K filed 2026-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 30,295,965 outstanding shares: 81% for, 1% against (82% of the company cast a for/against vote).
The 72 asset managers below cast 99.9% of the shares they voted on this item FOR (9,221,714 for, 1 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,023,908 | 1 | 0 | 0 | For |
| BlackRock | 1,561,151 | 0 | 0 | 0 | For |
| Fidelity | 1,349,200 | 0 | 0 | 0 | For |
| Principal | 754,854 | 0 | 0 | 0 | For |
| WASATCH FUNDS TRUST | 448,328 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 386,425 | 0 | 0 | 0 | For |
| TIAA | 358,474 | 0 | 0 | 0 | For |
| Dimensional | 336,242 | 0 | 0 | 0 | For |
| BUFFALO FUNDS | 264,287 | 0 | 0 | 0 | For |
| Charles Schwab | 241,865 | 0 | 0 | 0 | For |
| Allspring | 147,121 | 0 | 0 | 0 | For |
| EA Series Trust | 132,184 | 0 | 0 | 0 | For |
| State Street | 128,647 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 123,000 | 0 | 0 | 0 | For |
| Nuveen | 107,524 | 0 | 0 | 0 | For |
| Goldman Sachs | 103,702 | 0 | 0 | 0 | For |
| American Century | 78,975 | 0 | 0 | 0 | For |
| PRINCIPAL VARIABLE CONTRACTS FUNDS INC | 63,600 | 0 | 0 | 0 | For |
| Equitable | 63,424 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 46,712 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 46,342 | 0 | 0 | 0 | For |
| Lincoln Financial | 43,394 | 0 | 0 | 0 | For |
| Putnam | 37,658 | 0 | 0 | 0 | For |
| JPMorgan | 36,830 | 0 | 0 | 0 | For |
| Hartford | 31,224 | 0 | 0 | 0 | For |
Showing the 25 largest of 72 asset managers. See all 72 in the interactive database.
Combines 8 wordings of this item as funds reported it.
68% Majority: yes · of votes cast
Castle Biosciences, Inc.’s own tally for this item (“Elect Director: Ellen Goldberg”): 15,455,265 for, 7,118,166 withheld, per its Form 8-K filed 2026-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 30,295,965 outstanding shares: 51.0% for, 23% withheld (75% of the company cast a for/withheld vote).
The 69 asset managers below cast 100% of the shares they voted on this item FOR (6,841,135 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,021,364 | 0 | 2,546 | 0 | For |
| BlackRock | 1,561,151 | 0 | 0 | 0 | For |
| Fidelity | 698,824 | 0 | 650,376 | 0 | For |
| Principal | 0 | 0 | 754,854 | 0 | Abstain |
| WASATCH FUNDS TRUST | 448,328 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 386,425 | 0 | 0 | 0 | For |
| TIAA | 358,474 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 336,242 | 0 | Abstain |
| BUFFALO FUNDS | 264,287 | 0 | 0 | 0 | For |
| Charles Schwab | 241,865 | 0 | 0 | 0 | For |
| Allspring | 0 | 0 | 147,121 | 0 | Abstain |
| EA Series Trust | 132,184 | 0 | 0 | 0 | For |
| State Street | 75,614 | 0 | 53,033 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 123,000 | 0 | Abstain |
| Nuveen | 107,524 | 0 | 0 | 0 | For |
| Goldman Sachs | 103,702 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 78,975 | 0 | Abstain |
| PRINCIPAL VARIABLE CONTRACTS FUNDS INC | 0 | 0 | 63,600 | 0 | Abstain |
| Equitable | 47,404 | 0 | 16,020 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 46,712 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 0 | 0 | 46,342 | 0 | Abstain |
| Lincoln Financial | 24,259 | 0 | 19,135 | 0 | For |
| Putnam | 37,658 | 0 | 0 | 0 | For |
| JPMorgan | 36,830 | 0 | 0 | 0 | For |
| Hartford | 31,224 | 0 | 0 | 0 | For |
Showing the 25 largest of 69 asset managers. See all 69 in the interactive database.
Combines 8 wordings of this item as funds reported it.
69% Majority: yes · of votes cast
Castle Biosciences, Inc.’s own tally for this item (“Elect Director: Miles D. Harrison”): 15,607,369 for, 6,966,062 withheld, per its Form 8-K filed 2026-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 30,295,965 outstanding shares: 51.5% for, 23% withheld (75% of the company cast a for/withheld vote).
The 69 asset managers below cast 100% of the shares they voted on this item FOR (6,843,821 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,023,894 | 0 | 15 | 0 | For |
| BlackRock | 1,561,151 | 0 | 0 | 0 | For |
| Fidelity | 698,824 | 0 | 650,376 | 0 | For |
| Principal | 0 | 0 | 754,854 | 0 | Abstain |
| WASATCH FUNDS TRUST | 448,328 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 386,425 | 0 | 0 | 0 | For |
| TIAA | 358,474 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 336,242 | 0 | Abstain |
| BUFFALO FUNDS | 264,287 | 0 | 0 | 0 | For |
| Charles Schwab | 241,865 | 0 | 0 | 0 | For |
| Allspring | 0 | 0 | 147,121 | 0 | Abstain |
| EA Series Trust | 132,184 | 0 | 0 | 0 | For |
| State Street | 75,622 | 0 | 53,025 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 123,000 | 0 | Abstain |
| Nuveen | 107,524 | 0 | 0 | 0 | For |
| Goldman Sachs | 103,702 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 78,975 | 0 | Abstain |
| PRINCIPAL VARIABLE CONTRACTS FUNDS INC | 0 | 0 | 63,600 | 0 | Abstain |
| Equitable | 47,404 | 0 | 16,020 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 46,712 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 0 | 0 | 46,342 | 0 | Abstain |
| Lincoln Financial | 24,259 | 0 | 19,135 | 0 | For |
| Putnam | 37,658 | 0 | 0 | 0 | For |
| JPMorgan | 36,830 | 0 | 0 | 0 | For |
| Hartford | 31,224 | 0 | 0 | 0 | For |
Showing the 25 largest of 69 asset managers. See all 69 in the interactive database.
Combines 8 wordings of this item as funds reported it.
64% Majority: yes · of votes cast
Castle Biosciences, Inc.’s own tally for this item (“Elect Director: Tiffany P. Olson”): 14,380,655 for, 8,192,776 withheld, per its Form 8-K filed 2026-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 30,295,965 outstanding shares: 47.5% for, 27% withheld (75% of the company cast a for/withheld vote).
The 69 asset managers below cast 100% of the shares they voted on this item FOR (6,573,359 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,020,164 | 0 | 3,745 | 0 | For |
| BlackRock | 1,561,151 | 0 | 0 | 0 | For |
| Fidelity | 698,824 | 0 | 650,376 | 0 | For |
| Principal | 0 | 0 | 754,854 | 0 | Abstain |
| WASATCH FUNDS TRUST | 448,328 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 386,425 | 0 | 0 | 0 | For |
| TIAA | 358,474 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 336,242 | 0 | Abstain |
| BUFFALO FUNDS | 264,287 | 0 | 0 | 0 | For |
| Charles Schwab | 241,865 | 0 | 0 | 0 | For |
| Allspring | 0 | 0 | 147,121 | 0 | Abstain |
| EA Series Trust | 0 | 0 | 132,184 | 0 | Abstain |
| State Street | 67 | 0 | 128,580 | 0 | Abstain |
| BRIDGEWAY FUNDS INC | 0 | 0 | 123,000 | 0 | Abstain |
| Nuveen | 107,524 | 0 | 0 | 0 | For |
| Goldman Sachs | 103,702 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 78,975 | 0 | Abstain |
| PRINCIPAL VARIABLE CONTRACTS FUNDS INC | 0 | 0 | 63,600 | 0 | Abstain |
| Equitable | 47,404 | 0 | 16,020 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 46,712 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 0 | 0 | 46,342 | 0 | Abstain |
| Lincoln Financial | 4,859 | 0 | 38,535 | 0 | Abstain |
| Putnam | 37,658 | 0 | 0 | 0 | For |
| JPMorgan | 36,830 | 0 | 0 | 0 | For |
| Hartford | 31,224 | 0 | 0 | 0 | For |
Showing the 25 largest of 69 asset managers. See all 69 in the interactive database.
Ranked by the number of Castle Biosciences, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 30,295,965 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BlackRock | 9.37% |
| 2 | RTW INVESTMENTS, LP | 9.10% |
| 3 | Vanguard | 7.42% |
| 4 | Fidelity | 4.62% |
| 5 | Portolan Capital Management, LLC | 4.46% |
| 6 | PRINCIPAL GLOBAL INVESTORS | 3.69% |
| 7 | Principal | 2.49% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 2.40% |
| 9 | State Street | 2.26% |
| 10 | Allianz | 2.20% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| BlackRock | 9.85% | 13F |
| RTW Investments, LP | 9.10% | 13G |
| Vanguard Group | 7.26% | 13F |
| Portloan Capital Management, LLC | 5.32% | DEF14A |
| Principal Financial Group, Inc. | 5.23% | DEF14A |
| Dimensional Fund Advisors | 3.43% | 13F |
| Derek J. Maetzold | 2.71% | DEF14A |
| State Street | 2.54% | 13F |
| Renaissance Technologies | 1.76% | 13F |
| Millennium Management | 1.17% | 13F |
Percentages above are of 30,295,965 shares outstanding, as reported by Castle Biosciences, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Castle Biosciences, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At Castle Biosciences, Inc.'s shareholder meeting held 2026-05-28, in the 2025-2026 proxy season, 228 asset managers reported how they voted on 6 ballot items in their SEC Form N-PX filings, covering 1,596 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of our named executive officers, as… — FOR was 94% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Castle Biosciences, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-05-29.
Castle Biosciences, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).